Key result
fNIRS shows potential as a schizophrenia biomarker by detecting altered PFC activity linked to symptoms.
Why the study?
Functional near-infrared spectroscopy (fNIRS) shows promise as a noninvasive tool to measure brain activity related to clinical symptoms and outcomes in schizophrenia, but its clinical utility as a biomarker requires further exploration.
Can functional near-infrared spectroscopy (fNIRS) serve as a clinical biomarker in patients with schizophrenia?
Population
Patients with schizophrenia
Design
Review of fNIRS studies in psychiatry
Authors
Loading...
fNIRS may aid schizophrenia symptom monitoring; leaves open validation as a reliable clinical biomarker.
Can functional near-infrared spectroscopy (fNIRS) serve as a clinical biomarker in patients with schizophrenia?
fNIRS is a promising, noninvasive neuroimaging tool that may serve as a clinical biomarker for managing and monitoring schizophrenia.
Chou et al. (2019) conducted a review in Schizophrenia. Functional near-infrared spectroscopy (fNIRS) was evaluated. Functional near-infrared spectroscopy (fNIRS) shows potential as a clinical biomarker in schizophrenia by detecting altered prefrontal cortex activity associated with clinical symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: